Monique M A Verstegen
Overview
Explore the profile of Monique M A Verstegen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
72
Citations
2502
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Hengel E, van der Laan L, De Jonge J, Verstegen M
Bioengineering (Basel)
. 2025 Feb;
12(2).
PMID: 40001655
Whole-organ decellularization generates scaffolds containing native extracellular matrix (ECM) components with preserved tissue microarchitecture, providing a promising advancement in tissue engineering and regenerative medicine. Decellularization retains the ECM integrity which...
2.
Verstegen M, Coppes R, Beghin A, De Coppi P, Gerli M, de Graeff N, et al.
Nat Med
. 2025 Feb;
31(2):409-421.
PMID: 39901045
Organoids are innovative three-dimensional and self-organizing cell cultures of various lineages that can be used to study diverse tissues and organs. Human organoids have dramatically increased our understanding of developmental...
3.
Wu H, Yang A, Stelloo S, Roos F, Te Morsche R, Verkerk A, et al.
Dis Model Mech
. 2025 Jan;
18(1).
PMID: 39878507
Hepatic organoid cultures are a powerful model to study liver development and diseases in vitro. However, hepatocyte-like cells differentiated from these organoids remain immature compared to primary human hepatocytes (PHHs),...
4.
Ye S, Marsee A, van Tienderen G, Rezaeimoghaddam M, Sheikh H, Samsom R, et al.
Cell Rep Methods
. 2024 Nov;
4(11):100903.
PMID: 39561715
Conventional static culture of organoids necessitates weekly manual passaging and results in nonhomogeneous exposure of organoids to nutrients, oxygen, and toxic metabolites. Here, we developed a miniaturized spinning bioreactor, RPMotion,...
5.
Wang Z, Xing C, van der Laan L, Verstegen M, Spee B, Masereeuw R
Stem Cell Res Ther
. 2024 Mar;
15(1):78.
PMID: 38475870
Background: Drug induced bile duct injury is a frequently observed clinical problem leading to a wide range of pathological features. During the past decades, several agents have been identified with...
6.
Sleeboom J, van Tienderen G, Schenke-Layland K, van der Laan L, Khalil A, Verstegen M
Sci Transl Med
. 2024 Jan;
16(728):eadg3840.
PMID: 38170791
The extracellular matrix (ECM) is essential for cell support during homeostasis and plays a critical role in cancer. Although research often concentrates on the tumor's cellular aspect, attention is growing...
7.
Guo H, Liu D, Liu K, Hou Y, Li C, Li Q, et al.
Virol Sin
. 2023 Nov;
39(1):123-133.
PMID: 37984761
Hepatitis E virus (HEV) infection can cause severe complications and high mortality, particularly in pregnant women, organ transplant recipients, individuals with pre-existing liver disease and immunosuppressed patients. However, there are...
8.
Endothelial Cell Replacement of Human Veins, Modeling Vascular Repair and Endothelial Cell Chimerism
Tejeda-Mora H, den Hartog Y, Schurink I, Verstegen M, De Jonge J, van den Hoogen M, et al.
Stem Cells Dev
. 2023 Nov;
33(1-2):27-42.
PMID: 37950716
Allogeneic transplant organs are potentially highly immunogenic. The endothelial cells (ECs) located within the vascular system serve as the primary interface between the recipient's immune system and the donor organ,...
9.
Ober K, Roos F, van Tienderen G, Koten K, Klaassen A, Mi W, et al.
STAR Protoc
. 2023 Jul;
4(3):102431.
PMID: 37432852
Bile ducts are essential for bile transport and consist of complex branching tubular networks. Human patient-derived cholangiocyte develops a cystic rather than branching duct morphology. Here, we present a protocol...
10.
Magre L, Verstegen M, Buschow S, van der Laan L, Peppelenbosch M, Desai J
J Immunother Cancer
. 2023 May;
11(5).
PMID: 37220953
In the past decade, treatments targeting the immune system have revolutionized the cancer treatment field. Therapies such as immune checkpoint inhibitors have been approved as first-line treatment in a variety...